Drug Trial Radar · NCT07344558
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Dec 22, 2025
Primary completion
Jun 17, 2026
Study completion Jun 17, 2026
Sponsor
- Lead sponsor
- Mannkind CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
MNKD-201(Nintedanib DPI)Drug
MNKD-201 is a dry powder nintedanib formulation for oral inhalation.
PlaceboDrug
The placebo control in this study is an empty cartridge without any powder.
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Cohort 1) Events of BronchospasmTime frame: Up to Day 7
- (Cohort 2) Events of BronchospasmTime frame: Up to Day 7
- (Cohort 1) Changes in FEV1 (mL) from pre-dose to post-doseTime frame: Up to Day 7
- (Cohort 2) Changes in FEV1 (mL) from pre-dose to post-doseTime frame: Up to Day 7
- (Cohort 1) Changes in FEV1 / FVC ratio from pre-dose to post-doseTime frame: Up to Day 7
- (Cohort 2) Changes in FEV1 / FVC ratio from pre-dose to post-doseTime frame: Up to Day 7
- (Cohort 1) Rate of Study Drug DiscontinuationsTime frame: Up to Day 7
- (Cohort 2) Rate of Study Drug DiscontinuationsTime frame: Up to Day 7
- (Cohort 1) Rate of Study Drug Dose ReductionsTime frame: Up to Day 7
- (Cohort 2) Rate of Study Drug Dose ReductionsTime frame: Up to Day 7
- (Cohort 1) Rate of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 7
- (Cohort 2) Rate of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 7
- (Cohort 1) Rate of Treatment Related Adverse Events (TRAEs)Time frame: Up to Day 7
- (Cohort 2) Rate of Treatment Related Adverse Events (TRAEs)Time frame: Up to Day 7
- (Cohort 1) Rate of Serious Adverse Events (SAEs)Time frame: Up to Day 7
- (Cohort 2) Rate of Serious Adverse Events (SAEs)Time frame: Up to Day 7
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
VALDI
Fresno, California
Palmtree Clinical Research
Palm Springs, California
Innova Pharma Research
Doral, Florida
New Life Medical Research
Hialeah, Florida
New Access Research and Medical Services
Miami, Florida
Southeastern Research Center
Winston-Salem, North Carolina
Low Country Research
Charleston, South Carolina
Metroplex Pulmomary & Sleep Center
McKinney, Texas
Pulmonary Medicine Consultants
McKinney, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.